公开(公告)号：EP1654287B1

公开(公告)日：2010-08-11

申请号：EP04764037.0

申请日：2004-08-16

申请人： Merck Patent GmbH

发明人： CARR, Francis J. ,  WILLIAMS, Stephen ,  GILLIES, Stephen, D.

IPC分类号： A61K39/395 ,  A61P35/00 ,  C07K14/55 ,  C07K16/28 ,  C12N15/13 ,  C12N15/62

CPC分类号： C07K16/2887 ,  A61K2039/505 ,  C07K16/3076 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2319/00 ,  Y10S424/80 ,  Y10S424/801

公开(公告)号：EP1761559B1

公开(公告)日：2009-09-23

申请号：EP05766761.0

申请日：2005-06-28

申请人： Merck Patent GmbH

发明人： GILLIES, Stephen, D. ,  WATKINS, Nigel, John ,  BAKER, Matthew, Paul ,  LO, Kin-Ming

IPC分类号： C07K14/565

CPC分类号： C07K16/46 ,  A61K38/00 ,  A61K47/48423 ,  A61K47/6813 ,  C07K14/565 ,  C07K2319/30

摘要： Disclosed are Fc-interferon-beta (Fc-IFN-β) fusion proteins and nucleic acid molecules encoding them. The Fc- IFN-β fusion proteins include variants of the interferon-beta (IFN-β) protein that are altered to achieve enhanced biological activity, prolonged circulating half-life and greater solubility. Also disclosed are methods of producing the fusion proteins and methods of using the fusion proteins and/or nucleic acid molecules for treating diseases and conditions alleviated by the administration of interferon-beta.

公开(公告)号：EP1968633A1

公开(公告)日：2008-09-17

申请号：EP06829664.9

申请日：2006-12-15

申请人： Merck Patent GmbH ,  University of Montpellier I ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE ,  Centre Regional de Lutte Contre le Cancer "Val

发明人： GILLIES, Stephen, D. ,  AZRIA, David ,  LARBOURET, Christel ,  PELEGRIN, André

IPC分类号： A61K39/395 ,  A61P35/00

CPC分类号： C07K16/2863 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/31

摘要： The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody 'trastuzumab' (HERCEPTIN®) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody 'matuzumab' (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer.

公开(公告)号：EP1699822B1

公开(公告)日：2008-04-23

申请号：EP04804151.1

申请日：2004-12-21

申请人： Merck Patent GmbH

发明人： LAUDER, Scott ,  GILLIES, Stephen, D.

IPC分类号： C07K14/54 ,  C12N15/62 ,  A61K38/04

CPC分类号： C07K14/5418 ,  A61K38/2046 ,  A61K2039/55527 ,  C07K2319/00 ,  C07K2319/30

摘要： The invention relates to interleukin-7 (IL-7) fusion proteins, methods of their production and uses thereof. The fusion proteins comprise an immunoglobulin portion fused directly or indirectly to IL-7, which was modified at specific positions as compared to the wild­type IL-7 in order to improve biological and pharmaceutical properties. The proteins of the invention are particularly useful in treating disorders accompanied by immune deficiencies and particularly diseases which involve T-cell deficiencies.

公开(公告)号：EP1373301A2

公开(公告)日：2004-01-02

申请号：EP02757870.7

申请日：2002-03-30

申请人： MERCK PATENT GmbH

发明人： GILLIES, Stephen, D.

IPC分类号： C07K1/00

CPC分类号： C07K1/1077 ,  C07K14/505 ,  C07K14/5434 ,  C07K14/55 ,  C07K14/70578 ,  C07K16/30 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/30 ,  C07K2319/33 ,  C07K2319/40 ,  C07K2319/75 ,  C12N15/62 ,  Y10S424/809 ,  Y10S530/868

摘要： Disclosed are compositions and methods for producing fusion proteins with reduced immunogenicity. Fusion proteins of the invention include a junction region having an amino acid change that reduces the ability of a junctional epitope to bind to MHC Class II, thereby reducing its interaction with a T-cell receptor. Methods of the invention involve analyzing, changing, or modifying one or more amino acids in the junction region of a fusion protein in order to identify a T-cell epitope and reduce its ability to interact with a T-cell receptor. Compositions and methods of the invention are useful in therapy.

公开(公告)号：EP1366067A2

公开(公告)日：2003-12-03

申请号：EP02717581.9

申请日：2002-03-07

申请人： MERCK PATENT GmbH

发明人： GILLIES, Stephen, D. ,  WAY, Jeffrey ,  LO, Kin-Ming

IPC分类号： C07K14/00 ,  C07K16/00 ,  A61K39/44 ,  C07H21/04 ,  C12P21/06

CPC分类号： C07K16/30 ,  C07K2317/52 ,  C07K2317/53 ,  C07K2319/00 ,  C07K2319/30

摘要： Disclosed are methods and compositions for efficiently expressing antibody fusion proteins. Antibody fusion proteins of the invention include a hybrid antibody moiety containing sequences from more than one type of antibody and/or mutant antibody sequences. Hybrid antibody fusion proteins of the invention may be produced at high levels and may combine functional properties characteristic of different antibody types in addition to functional properties of a non-antibody moiety.

公开(公告)号：EP1252192A2

公开(公告)日：2002-10-30

申请号：EP01916083.7

申请日：2001-02-09

申请人： MERCK PATENT GmbH

发明人： GILLIES, Stephen, D. ,  BURGER, Christa ,  LO, Kin, Ming

IPC分类号： C07K19/00 ,  G01N33/68

CPC分类号： C07K5/1013 ,  A61K47/6813 ,  A61K47/6851 ,  A61K2039/505 ,  C07K14/525 ,  C07K14/55 ,  C07K16/00 ,  C07K16/30 ,  C07K19/00 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/73 ,  C07K2319/00

摘要： Disclosed are compositions and methods for enhancing the circulating half-life of antibody-based fusion proteins. Disclosed methods and compositions rely on altering the amino acid sequence of the junction region between the antibody moiety and the fused protein moiety in an antibody-based fusion protein. An antibody-based fusion protein with an altered amino acid sequence in the junction region has a greater circulating half-life when administered to a mammal. Disclosed methods and compositions are particularly useful for reducing tumor size and metastasis in a mammal.